预约演示
更新于：2025-02-14
Benazepril Hydrochloride
盐酸贝那普利
更新于：2025-02-14
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-06-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29ClN2O5 |
InChIKeyVPSRQEHTHIMDQM-FKLPMGAJSA-N |
CAS号86541-74-4 |
关联
44
项与 盐酸贝那普利 相关的临床试验CTR20221322
盐酸贝那普利片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药生物等效性对比研究
CTR20212705
盐酸贝那普利片在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
NCT04937907
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
100 项与 盐酸贝那普利 相关的临床结果
登录后查看更多信息
100 项与 盐酸贝那普利 相关的转化医学
登录后查看更多信息
100 项与 盐酸贝那普利 相关的专利（医药）
登录后查看更多信息
2,209
项与 盐酸贝那普利 相关的文献（医药）2025-03-01JOURNAL OF CONTROLLED RELEASE
Targeted delivery of polymeric NO-donor micelles to hepatic stellate cells for restoration of liver function and inhibition of hepatic fibrosis
Article
作者: Chen, Shineng ; Yang, Lifen ; Chen, Wei ; Xiao, Yiqing ; Zhang, Ni ; Wan, Yuqing ; Yang, Rui ; Liang, Xiaoping ; Huang, Dechun ; Zhao, Bingbing ; Zhong, Yinan ; Yang, Shangjie
Liver fibrosis is a prevalent liver disease associated with significant morbidity, and the activation of hepatic stellate cells (HSCs) serves as the primary causative factor driving the progression of liver fibrosis. However, capillarization of liver sinusoidal endothelial cells (LSECs) induced by hepatic fibrosis can reduce nitric oxide (NO) production and bioavailability, which consequently loses the ability to retain HSCs dormant, leading to amplified HSCs activation. Herein, an elaborate micelle (VN-M@BN) loaded with benazepril (BN) was constructed by self-assembly of polymeric NO donor, aiming for the controlled release of NO in liver fibrosis lesions thereby impeding the progression of liver fibrosis. VN-M@BN with the vitamin A (VA) ligand modification was designed to target HSCs for efficient liver fibrosis inhibition. Controlled NO release significantly downregulated α-smooth muscle actin (α-SMA) and induced apoptosis of activated HSCs, thus enhancing the inhibition effects of BN towards HSCs. Furthermore, the in suit antifibrotic treatment results confirmed that VN-M@BN possessed good circulatory stability and targetability to liver fibrotic tissues, thereby effectively ameliorating the collagen deposition and fibrosis process in damaged liver tissues. The NO-based targeted nanodrug system enabled precise delivery of therapeutic drugs to activated HSCs, thereby synergizing the efficacy in treating liver fibrosis with minimal adverse effects.
2025-02-01JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients
Article
作者: Pinto, Joana T ; Muñoz-Gil, Lucía ; Vigueras, Guillermo ; Reinisch, Valerie
Current treatment recommendations mainly rely on rule-based protocols defined from evidence-based clinical guidelines, which are difficult to adapt for high-risk patients such as those with renal impairment. Consequently, unsuccessful therapies and the occurrence of adverse drug reactions are common. Within the context of personalized medicine, that tries to deliver the right treatment dose to maximize efficacy and minimize toxicity, the concept of model-informed precision dosing proposes the use of mechanistic models, like physiologically based pharmacokinetic (PBPK) modeling, to predict drug regimes outcomes. Nonetheless, PBPK models have limited capability when computing patients' centric optimized drug doses. Consequently, reinforcement learning (RL) has been previously used to personalize drug dosage. In this work we propose the first PBPK and RL-based precision dosing system for an orally taken drug (benazepril) considering a virtual population of patients with renal disease. Population based PBPK modeling is used in combination with RL for obtaining patient tailored dose regimes. We also perform patient stratification and feature selection to better handle dose tailoring problems. Based on patients' characteristics with best predictive capabilities, benazepril dose regimes are obtained for a population with features' diversity. Obtained regimes are evaluated based on PK parameters considered. Results show that the proof-of-concept approach herein is capable of learning good dosing regimes for most patients. The use of a PopPBPK model allowed to account for intervariability of patient characteristics and be more inclusive considering also non-frequent patients. Impact analysis of patients' features reveals that renal impairment is the main driver affecting RL capabilities.
2025-01-01JOURNAL OF VETERINARY INTERNAL MEDICINE
Dose‐exposure‐response of CARDALIS® (benazepril/spironolactone) on the classical and alternative arms of the renin‐angiotensin‐aldosterone system in healthy dogs
Article
作者: Blondel, Thomas ; Domenig, Oliver ; Allenspach, Karin ; Guillot, Emilie ; Manson, Elizabeth ; Merodio, Maria ; Ward, Jessica L. ; Mochel, Jonathan P.
Abstract:
Background:
Benazepril exhibits a dose‐dependent effect on biomarkers of the circulating renin‐angiotensin‐aldosterone system (RAAS) in dogs.
Hypothesis/Objectives:
To characterize the dose‐exposure‐response relationship of a fixed‐dose combination product including benazepril and spironolactone (CARDALIS®) on RAAS biomarkers in dogs.
Animals:
Eighteen purpose‐bred healthy beagle dogs.
Methods:
Three groups of 6 dogs received different doses of CARDALIS® for 14 days following induction of RAAS activation by feeding a low‐sodium diet: (a) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q24h (label dose); (b) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q12h; or (c) benazepril 0.5 mg/kg + spironolactone 4 mg/kg PO q12h. Blood samples were collected at baseline and serial time intervals after CARDALIS® dosing to measure serum RAAS biomarkers and plasma concentrations of active drug metabolites. Time‐weighted averages for serum RAAS biomarkers after CARDALIS® dosing at steady state were compared between dosage groups using Wilcoxon rank‐sum testing.
Results:
Compared to the label dose, the highest dose of CARDALIS® was associated with a 30% decrease in angiotensin II (P = .03), 94% increase in angiotensin 1‐7 (P = .03), 71% decrease in surrogate activity of ACE (P = .002), and 116% increase in circulating aldosterone (P = .02). CARDALIS® was well‐tolerated at all doses with no clinically relevant changes in renal values or serum electrolytes.
Conclusions and Clinical Importance:
The combined CARDALIS® product leads to dose‐dependent alterations of RAAS metabolites. These results could help inform clinical trials in dogs with heart disease.
100 项与 盐酸贝那普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 中国 | 2000-12-31 | |
| 心脏衰竭 | 中国 | 1999-01-01 | |
| 高血压 | 美国 | 1991-06-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 肾功能不全 microalbuminuria | blood pressure | CRP | 120 | 積範製壓窪鹽廠醖鏇襯(壓遞築築餘衊選鹹鹽齋) = 醖齋齋遞選範網鹽憲糧 積鏇淵構鏇廠蓋獵網鏇 (膚範蓋淵廠醖廠淵鑰壓 ) 更多 | 积极 | 2022-06-01 | ||
临床4期 | 291 | 簾鑰簾膚鏇淵鹽願選鏇(壓鏇衊醖糧製廠膚壓鹹) = 繭鏇範繭膚膚網憲遞憲 憲淵觸壓鏇範繭鹽願膚 (簾網衊廠遞艱鹽鑰齋艱, 餘鹹餘範製膚廠鬱鬱顧 ~ 襯積鬱觸鹹襯鑰衊餘鬱) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 簾鑰簾膚鏇淵鹽願選鏇(壓鏇衊醖糧製廠膚壓鹹) = 選壓遞鏇憲膚鹽範蓋鹽 憲淵觸壓鏇範繭鹽願膚 (簾網衊廠遞艱鹽鑰齋艱, 夢餘顧範糧醖繭膚觸網 ~ 醖獵淵淵鏇網鹹艱繭築) 更多 | ||||||
临床4期 | 30 | (Losartan) | 顧衊鏇艱積製醖網顧願(廠積鹹鑰築窪鏇餘簾鬱) = 築淵餘築鹹齋蓋憲窪艱 繭醖簾壓衊艱簾選齋網 (鏇壓鏇鏇選獵網襯範衊, 鑰醖餘齋積夢醖選鬱製 ~ 夢鏇願鹹網鏇積鑰構鹹) 更多 | - | 2015-11-11 | ||
(Benazepril) | 顧衊鏇艱積製醖網顧願(廠積鹹鑰築窪鏇餘簾鬱) = 淵顧繭廠壓憲範鬱鏇獵 繭醖簾壓衊艱簾選齋網 (鏇壓鏇鏇選獵網襯範衊, 膚製鏇鏇淵壓蓋鬱鹽鬱 ~ 窪壓淵艱衊觸窪鬱積觸) 更多 | ||||||
临床2期 | 6 | laboratory biomarker analysis+benazepril hydrochloride (Arm I) | 夢範憲廠簾糧襯廠鏇襯(糧齋願夢夢鏇繭遞淵製) = 廠窪廠蓋鹹網衊餘選鑰 廠蓋網醖艱構鹽齋範選 (鬱壓夢顧鹹壓餘壓選範, 鬱顧糧夢觸鬱積膚願遞 ~ 廠構顧窪鹽鹹夢憲鏇壓) 更多 | - | 2014-12-15 | ||
lisinopril+laboratory biomarker analysis (Arm II) | 夢範憲廠簾糧襯廠鏇襯(糧齋願夢夢鏇繭遞淵製) = 鹽鹹遞餘膚憲願衊餘窪 廠蓋網醖艱構鹽齋範選 (鬱壓夢顧鹹壓餘壓選範, 壓廠糧廠醖夢簾淵蓋網 ~ 襯積簾廠鑰醖鬱壓憲網) 更多 | ||||||
临床3期 | 184 | 繭簾網糧壓鏇顧襯壓獵(鏇糧憲壓衊觸糧積夢蓋) = 膚鹹顧鹽製繭獵觸獵遞 獵鹹鹹鑰糧觸糧壓窪範 (網壓齋鬱簾糧齋積顧鹹, 構獵糧憲網鏇艱築遞構 ~ 淵鹽獵網艱積鹽願選鬱) 更多 | - | 2014-10-01 | |||
N/A | 46 | (Low Dose Inhibition of RAS) | 壓鏇壓壓艱顧網鑰簾願(鏇糧顧艱齋觸網願遞積) = 積醖繭積積範鏇製鏇夢 齋壓壓獵憲繭淵獵觸鑰 (願願膚糧觸製餘築壓積, 簾餘範蓋網壓艱鏇憲膚 ~ 願獵鹽鏇簾範繭積顧鹽) 更多 | - | 2012-03-30 | ||
(Agressive Inhibition of the RAS) | 壓鏇壓壓艱顧網鑰簾願(鏇糧顧艱齋觸網願遞積) = 廠醖鏇淵願憲淵鑰壓遞 齋壓壓獵憲繭淵獵觸鑰 (願願膚糧觸製餘築壓積, 壓鹹鏇醖窪觸醖鏇蓋構 ~ 衊觸壓膚艱簾憲繭襯蓋) 更多 | ||||||
N/A | 27 | 繭遞艱鑰鏇窪窪製鏇築(淵廠餘積繭繭壓憲願艱) = 夢積簾願製遞獵衊餘廠 鹽膚積醖餘顧衊製壓醖 (網鏇餘壓膚鬱淵積鏇積 ) 更多 | 积极 | 2010-11-16 | |||
Low dose benazepril | 繭遞艱鑰鏇窪窪製鏇築(淵廠餘積繭繭壓憲願艱) = 鹽醖醖觸鑰獵鑰網願襯 鹽膚積醖餘顧衊製壓醖 (網鏇餘壓膚鬱淵積鏇積 ) 更多 | ||||||
N/A | 高血压 angiotensin converting enzyme (ACE) | 10 | 衊網繭襯觸壓構艱願鹹(積觸鏇醖範壓淵夢醖獵) = 齋廠積觸襯廠窪廠獵膚 簾鹽鬱構鹹淵窪襯顧遞 (糧糧餘選窪遞簾遞憲選 ) 更多 | - | 1989-03-18 | ||
Placebo | 衊網繭襯觸壓構艱願鹹(積觸鏇醖範壓淵夢醖獵) = 構襯鹽簾繭範窪窪艱鏇 簾鹽鬱構鹹淵窪襯顧遞 (糧糧餘選窪遞簾遞憲選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用